Annotation of HCSC Label for lidocaine / prilocaine and CYB5R3, G6PD

Actionable PGxLearn more about Label Annotation Levels of Evidence(opens in new window)
Alternate DrugLearn more about the Alternate Drug tag(opens in new window)Other GuidanceLearn more about the Other Guidance tag(opens in new window)Prescribing InfoLearn more about the Prescribing Info tag(opens in new window)

PharmGKB ID

PA166357841

Summary

The HCSC-approved product monograph for lidocaine and prilocaine (ORAQIX) states that patients with G6PD deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia, and that ORAQIX should not be used in those patients with congenital or idiopathic methemoglobinemia.

Prescribing

Patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia. ORAQIX® (Lidocaine and Prilocaine Periodontal Gel) should not be used in those patients with congenital or idiopathic methemoglobinemia.

To minimize the risk of methemoglobinemai, BEFORE you use ORAQIX® talk to your dentist/dental hygienist if: [...]

  • you have glucose 6-phosphate deficiencies.

Annotation

Excerpts from the lidocaine and prilocaine (ORAQIX) product monograph:

ORAQIX® (Lidocaine and Prilocaine Periodontal Gel) is contraindicated: [...]

  • in patients with congenital or idiopathic methemoglobinemia

Patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia. ORAQIX® (Lidocaine and Prilocaine Periodontal Gel) should not be used in those patients with congenital or idiopathic methemoglobinemia.

Very young patients or patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia.

To minimize the risk of methemoglobinemai, BEFORE you use ORAQIX® talk to your dentist/dental hygienist if: [...]

  • you have glucose 6-phosphate deficiencies.

For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the lidocaine and prilocaine product monograph.

NOTE: While the CYB5R3 gene is not explicitly mentioned in the product monograph, variants in this gene are associated with congenital methemoglobinemia I and II.

*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.

Evidence for Clinical Annotations

This annotation has not been used as evidence for any clinical annotations.

History

No history available.